NCT04166773

A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH)

A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing the Efficacy and Safety of Tirzepatide Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 190 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to see if the study drug, tirzepatide administered once weekly, is safe and effective as a treatment for Nonalcoholic Steatohepatitis (NASH).

Conditions

• Nonalcoholic Steatohepatitis

Interventions

Type	Name	Description
DRUG	Tirzepatide	Administered SC
DRUG	Placebo	Administered SC

Timeline

• Start date: 2019-11-19
• Primary completion: 2023-12-11
• Completion: 2024-01-10
• First posted: 2019-11-18
• Last updated: 2025-01-24
• Results posted: 2025-01-24

Locations

112 sites across 10 countries: United States, Belgium, France, Israel, Italy, Japan, Mexico, Poland, Spain, United Kingdom

Regulatory

• FDA-regulated drug study